» Articles » PMID: 38755184

Common Food Additive Carrageenan Inhibits Proglucagon Expression and GLP-1 Secretion by Human Enteroendocrine L-cells

Overview
Journal Nutr Diabetes
Date 2024 May 16
PMID 38755184
Authors
Affiliations
Soon will be listed here.
Abstract

Proglucagon mRNA expression and GLP-1 secretion by cultured human L-cells (NCI-H716) were inhibited following exposure to λ-carrageenan, a commonly used additive in processed foods. Carrageenan is composed of sulfated or unsulfated galactose residues linked in alternating alpha-1,3 and beta-1,4 bonds and resembles the endogenous sulfated glycosaminoglycans. However, carrageenan has unusual alpha-1,3-galactosidic bonds, which are not innate to human cells and are implicated in immune responses. Exposure to carrageenan predictably causes inflammation, and carrageenan impairs glucose tolerance and contributes to insulin resistance. When cultured human L-cells were deprived overnight of glucose and serum and then exposed to high glucose, 10% FBS, and λ-carrageenan (1 µg/ml) for 10 minutes, 1 h, and 24 h, mRNA expression of proglucagon and secretion of GLP-1 were significantly reduced, compared to control cells not exposed to carrageenan. mRNA expression of proglucagon by mouse L-cells (STC-1) was also significantly reduced and supports the findings in the human cells. Exposure of co-cultured human intestinal epithelial cells (LS174T) to the spent media of the carrageenan-treated L-cells led to a decline in mRNA expression of GLUT-2 at 24 h. These findings suggest that ingestion of carrageenan-containing processed foods may impair the production of GLP-1, counteract the effect of GLP-1 receptor agonists and induce secondary effects on intestinal epithelial cells.

Citing Articles

Ultra-Processed Foods and Type 2 Diabetes Mellitus: What Is the Evidence So Far?.

Vallianou N, Evangelopoulos A, Tzivaki I, Daskalopoulou S, Adamou A, Michalaki Zafeiri G Biomolecules. 2025; 15(2).

PMID: 40001610 PMC: 11852733. DOI: 10.3390/biom15020307.


Association Between Ultraprocessed Food Consumption and Metabolic Disorders in Children and Adolescents with Obesity.

Lee G, Lim J, Joung H, Yoon D Nutrients. 2024; 16(20).

PMID: 39458518 PMC: 11510381. DOI: 10.3390/nu16203524.

References
1.
Bhattacharyya S, Feferman L, Tobacman J . Distinct Effects of Carrageenan and High-Fat Consumption on the Mechanisms of Insulin Resistance in Nonobese and Obese Models of Type 2 Diabetes. J Diabetes Res. 2019; 2019:9582714. PMC: 6501429. DOI: 10.1155/2019/9582714. View

2.
Kuhre R, Albrechtsen N, Deacon C, Balk-Moller E, Rehfeld J, Reimann F . Peptide production and secretion in GLUTag, NCI-H716, and STC-1 cells: a comparison to native L-cells. J Mol Endocrinol. 2016; 56(3):201-11. PMC: 7212058. DOI: 10.1530/JME-15-0293. View

3.
Reimer R, Darimont C, Gremlich S, Nicolas-Metral V, Ruegg U, Mace K . A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology. 2001; 142(10):4522-8. DOI: 10.1210/endo.142.10.8415. View

4.
Feferman L, Bhattacharyya S, Oates E, Haggerty N, Wang T, Varady K . Carrageenan-Free Diet Shows Improved Glucose Tolerance and Insulin Signaling in Prediabetes: A Randomized, Pilot Clinical Trial. J Diabetes Res. 2020; 2020:8267980. PMC: 7191375. DOI: 10.1155/2020/8267980. View

5.
Tobacman J, Bhattacharyya S . Profound Impact of Decline in N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on Molecular Pathophysiology and Human Diseases. Int J Mol Sci. 2022; 23(21). PMC: 9654056. DOI: 10.3390/ijms232113146. View